Rockwell medical, inc. (RMTI)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash Flows From Operating Activities:
Net (Loss)

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Loss

-33,433

-34,128

-36,201

-33,316

-35,254

-32,125

0

0

0

-

-

-

-

-19,802

-20,518

-18,369

-15,545

-14,420

-15,034

-16,587

-17,220

-21,327

-23,275

-32,516

-41,209

-48,783

-54,124

-58,792

-58,834

-54,021

-49,300

-36,466

-29,099

-21,444

0

0

0

Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Depreciation and Amortization

810

788

765

749

708

650

596

536

513

514

563

625

692

762

797

809

814

822

837

898

946

996

1,022

1,011

1,014

1,007

1,011

1,034

1,060

1,087

1,076

1,080

1,123

1,176

0

0

0

Share Based Compensation - Non-employee

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,862

2,448

2,908

3,003

2,322

0

0

0

-

-

-

-

Share Based Compensation - Non-employee

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Stock-based Compensation

4,369

4,951

5,856

5,594

5,458

4,387

3,567

4,595

5,361

7,174

8,585

9,513

9,926

10,346

10,585

9,116

8,274

8,887

9,898

10,682

11,213

10,094

7,693

7,476

6,672

5,849

5,701

5,365

5,126

4,979

4,768

4,320

4,214

4,065

0

0

0

Increase in Inventory Reserves

1,260

1,271

6,612

3,048

6,748

8,784

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of Right of Use Asset

1,776

1,864

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of Debt Financing Costs and Accretion of Debt Discount

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted Stock Tendered in Satisfaction of Tax Liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on Disposal of Assets

-

-

-

-

-

-4

-10

-9

-10

-10

-4

-11

-11

-8

-8

-3

-3

-5

-6

-4

-8

-7

-5

-15

-12

-16

-7

1

-12

-17

-27

-29

-33

-29

0

0

0

Amortization of Debt Issuance Costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

882

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash Interest Expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

874

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Realized (Gain) on Sale of Investments Available-for-Sale

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign Currency Translation Adjustment

-4

0

-2

3

8

10

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in Assets and Liabilities:
(Increase) Decrease in Accounts Receivable, net

-2,124

-2,776

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in Accounts Receivable

-

-

-

-

-

-

-

-

321

962

-1,672

-1,724

330

1,162

2,134

3,651

1,557

574

1,706

-280

565

-106

-32

-357

-361

146

-96

220

247

209

60

-141

-472

-284

0

0

0

Decrease in Insurance Receivable

0

-371

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Increase) Decrease in Inventory

673

-316

4,211

2,080

732

835

-6,403

-4,186

-2,694

-343

4,598

5,490

7,094

6,095

4,344

4,694

3,967

3,951

4,433

3,530

2,286

1,120

167

-132

44

150

142

154

455

145

437

404

-372

-432

0

0

0

Decrease in Prepaid and Other Assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease (Increase) in Other Assets

-

-

-

-

-

165

-115

775

-343

-264

-370

826

1,026

1,230

722

75

176

360

710

-2,041

-4

13

253

2,252

-168

-669

-1,228

-1,624

-1,872

-1,855

-1,234

762

-109

2,457

0

0

0

Increase in Accounts Payable

-1,399

-1,473

-3,737

858

509

269

2,741

-663

68

-1,636

791

-1,106

-477

1,863

-1,826

656

-717

-1,299

52

-1,956

4

-3,391

-1,940

-2,027

-10,967

-6,147

-979

1,892

11,438

9,469

4,481

3,192

1,960

1,705

0

0

0

Decrease in Settlement Payable

-109

-312

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in Lease Liability

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase in Other Liabilities

-1,113

-532

1,153

-14

3,086

271

-612

417

-3,020

634

-492

-405

2,859

191

666

1,490

-1,613

-413

-1,098

-564

136

-2,345

-5,723

-5,207

-7,306

-5,295

-5,434

-2,519

3,202

3,829

9,498

7,311

5,610

5,028

0

0

0

Decrease in Deferred License Revenue

-2,135

-2,252

-2,365

-2,375

-3,529

-2,394

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Decrease) in Deferred License Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-2,082

-2,065

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase (decrease) in deferred drug license revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred License Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in Assets and Liabilities

3,158

1,975

7,279

4,571

674

3,432

-4,429

-1,411

2,640

3,684

3,686

7,382

7,399

3,793

6,591

4,447

6,148

8,681

-10,115

-14,775

-16,293

-12,727

8,051

8,997

17,787

11,069

5,230

-623

-15,810

-14,799

-14,716

-9,478

-8,524

-4,993

0

0

0

Cash Used In Operating Activities

-28,369

-27,254

-27,738

-26,341

-21,236

-20,419

-19,446

-18,852

-20,642

-21,112

-15,764

-18,275

-16,464

-12,452

-12,778

-9,919

-11,079

-13,328

4,015

8,166

11,309

4,257

-21,440

-31,442

-49,722

-50,664

-49,692

-48,795

-33,752

-30,746

-27,109

-20,610

-14,523

-10,783

0

0

0

Cash Flows From Investing Activities:
Purchase of Investments Available-for-Sale

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of Investments Available-for-Sale

-

-

-

-

-

-20,178

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of Securities Available for Sale

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,100

0

0

0

-

-

-

-

-

-

-

-

2,000

0

0

0

Sale of Investments Available-for-Sale

37,164

38,265

34,778

46,560

45,606

33,895

41,392

24,700

52,938

51,918

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of Equipment

668

587

603

708

710

744

1,566

1,622

1,676

1,682

733

527

314

355

806

835

939

815

408

464

432

684

771

770

830

654

622

578

572

507

458

452

388

421

0

0

0

Purchase of Research and Development Licenses (Related Party)

500

750

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds on Sale of Assets

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

4

0

0

0

-

-

-

-

6

6

6

7

1

0

0

0

-

-

-

0

Cash Provided By Investing Activities

-5,740

-4,749

-2,721

5,744

16,822

12,723

19,844

12,012

14,111

14,502

2,531

5,202

-1,572

-1,644

527

-1,796

-21,271

-21,141

-31,834

-31,859

-6,551

-8,808

203

-9,796

-14,832

-12,649

-28

13,453

11,459

11,518

982

-2,458

-473

-587

0

0

0

Cash Flows From Financing Activities:
Proceeds from Term Loan

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the Issuance of Common Shares and Purchase Warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

80

0

0

0

-

-

-

-

79,569

3,605

3,174

40,552

51,596

50,872

50,909

14,432

18,231

0

0

0

-

-

-

-

Debt Issuance Costs

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on Short Term Note Payable

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

15

18

0

0

0

Proceeds from the Issuance of Common Stock / Public Offering

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Offering Costs from the Issuance of Common Stock / Public Offering

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the Exercise of Employee Stock Options

0

147

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repurchase of Common Shares to Pay Employee Withholding Taxes

-374

-279

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash Provided By Financing Activities

50,589

21,084

0

0

0

-

-

-

-

-

-

-

-

80

-1,627

-1,607

-974

-132

57,974

57,980

57,913

58,469

3,041

3,145

59,440

70,484

69,760

69,824

14,428

18,224

18,880

20,221

20,683

4,822

0

0

0

Increase (Decrease) In Cash and Cash Equivalents

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effects of Exchange Rate Changes

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease In Cash and Cash Equivalents

-

-

-

-

-

-

-

-

-8,695

-8,773

-15,405

-15,357

-18,033

-14,017

-13,879

-13,324

-33,325

-34,602

30,155

34,287

62,671

53,919

-18,195

-38,093

-5,113

7,169

20,038

34,482

-7,865

-1,003

-7,247

-2,848

5,687

-6,548

0

0

0

Supplemental Disclosure of Cash Flow Information:
Cash Paid for Interest

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental Disclosure of Noncash Investing and Financing Activities:
Change in Unrealized Loss on Marketable Securities Available-for-Sale

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Delivery of Common Stock Underlying Restricted Stock Units

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance Costs related to Debt Financing, not yet paid

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair Value of Warrants issued related to Debt Financing

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest Paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

3,518

2,537

2,419

1,782

1,154

522

2

0

0

1

1

1

1

0

0

0